The answer to this blatantly misleading thread remains an...

The answer to this blatantly misleading thread remains an unequivocal NO.

What is certain is that one AZD0466 Phase One trial was terminated, one AZD0466 Phase One trial is now paused, and a third AZD0466 trial apparently continues at this point in time.

It’s looking more and more likely, in my opinion, that an interim Chair and interim CEO will be running the 2023 AGM.

Are Rob and Jackie so bold as to front up to an AGM in front of angry investors and institutional shareholders with a share price in the 20s when the last cap raise was at $1.50? Maybe they are.

P.S. A decent company would have paused trading today and had an investor briefing to thoroughly inform investors of this AZD0466 development. Instead, as always, shareholders are left guessing and speculating. Poor form.

P.S.S. We’re now into our 5th year of the supposed AstraZeneca Option Agreement and we’ve heard nothing but crickets chirping. Without evidence to the contrary one can only assume that the pre-clinical studies are not setting the world on fire.

DYO Thorough R